Trial site
Hämatologisch Onkologische Praxis Eppendorf (HOPE)
Hamburg, 22297, GermanyNot linked to an institution yet
- 11running trials
- 2closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 24 trials
- Phase 34 trials
- Phase 12 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Completed2 trials
- Not yet recruiting1 trial
- Suspended1 trial
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest5 trials
- AbbVie1 trial
- AstraZeneca1 trial
- BioNTech SE1 trial
- Daiichi Sankyo1 trial
- and 5 more
Running trials
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
NCT07176312· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Contact: Alexander Stein, Prof. Dr.
Recruiting
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
NCT07059299· Phase 1· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Contact: Alexander Stein, Prof. Dr.
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631· Phase 1/2· BioNTech SE· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· Phase 3· Daiichi Sankyo· Source
Recruiting
Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT06787105· iOMEDICO AG· Source
Contact: Eray Gökkurt, Dr. med.
Active, not recruiting
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310· Phase 2· AbbVie· Source
Active, not recruiting
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
NCT06178445· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Active, not recruiting
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
NCT05993234· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source
Active, not recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
NCT03252938· Phase 1· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error